Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.
作者信息
Brauch Hiltrud, Schroth Werner, Goetz Matthew P, Mürdter Thomas E, Winter Stefan, Ingle James N, Schwab Matthias, Eichelbaum Michel
机构信息
Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
出版信息
J Clin Oncol. 2013 Jan 10;31(2):176-80. doi: 10.1200/JCO.2012.44.6625. Epub 2012 Oct 22.
Abstract
摘要
相似文献
1
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.他莫昔芬在绝经后乳腺癌中的应用：细胞色素P450 2D6起重要作用。
J Clin Oncol. 2013 Jan 10;31(2):176-80. doi: 10.1200/JCO.2012.44.6625. Epub 2012 Oct 22.
2
CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer.细胞色素P450 2D6（CYP2D6）基因分型不应用于决定绝经后乳腺癌患者的他莫昔芬治疗方案。
J Clin Oncol. 2013 Jul 20;31(21):2753-5. doi: 10.1200/JCO.2013.49.4278. Epub 2013 Jun 17.
3
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.CYP2D6 基因型与内分泌治疗反应性乳腺癌绝经后妇女的关系：乳腺国际研究组 1-98 试验。
J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.
4
Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.CYP2D6基因变异对绝经后早期乳腺癌女性他莫昔芬治疗结局的预测作用
Br J Clin Pharmacol. 2014 Apr;77(4):695-703. doi: 10.1111/bcp.12229.
5
CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer.CYP2D6基因分型与他莫昔芬在绝经后乳腺癌治疗中的应用
Br J Clin Pharmacol. 2014 Aug;78(2):431-2. doi: 10.1111/bcp.12329.
6
CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a reply.CYP2D6基因分型与他莫昔芬在绝经后乳腺癌治疗中的应用——答复
Br J Clin Pharmacol. 2014 Aug;78(2):433-4. doi: 10.1111/bcp.12330.
7
Why should results from metastatic trials no longer matter for early-stage disease?为什么转移性试验的结果对早期疾病不再重要？
J Clin Oncol. 2013 Jul 20;31(21):2753. doi: 10.1200/JCO.2012.48.5508. Epub 2013 Jun 17.
8
Reply to A.-S. Dieudonné et al and J.M. Rae et al.对A.-S.迪厄多内等人以及J.M.雷伊等人的回复
J Clin Oncol. 2013 Jul 20;31(21):2755-6. doi: 10.1200/JCO.2013.49.6661.
9
CYP2D6 and tamoxifen: DNA matters in breast cancer.细胞色素P450 2D6与他莫昔芬：DNA在乳腺癌中的重要作用
Nat Rev Cancer. 2009 Aug;9(8):576-86. doi: 10.1038/nrc2683.
10
CYP2D6 genotype and tamoxifen response.细胞色素P450 2D6基因分型与他莫昔芬反应
Breast Cancer Res. 2005 Jul 29;7(5):E6. doi: 10.1186/bcr1297.
引用本文的文献
1
Germline variants in cancer therapy.癌症治疗中的种系变异
Cancer Drug Resist. 2019 Mar 19;2(1):18-30. doi: 10.20517/cdr.2019.05. eCollection 2019.
2
Tamoxifen and oxidative stress: an overlooked connection.他莫昔芬与氧化应激：一种被忽视的关联。
Discov Oncol. 2021 May 27;12(1):17. doi: 10.1007/s12672-021-00411-y.
3
Manipulating Estrogenic/Anti-Estrogenic Activity of Triphenylethylenes towards Development of Novel Anti-Neoplastic SERMs.三苯乙烯类化合物的雌激素/抗雌激素活性调控及其新型抗乳腺癌选择性雌激素受体调节剂的研发
Int J Mol Sci. 2021 Nov 22;22(22):12575. doi: 10.3390/ijms222212575.
4
Transdermal Delivery of Chemotherapeutics: Strategies, Requirements, and Opportunities.化疗药物的经皮给药：策略、要求与机遇
Pharmaceutics. 2021 Jun 26;13(7):960. doi: 10.3390/pharmaceutics13070960.
5
Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio.使用 N-去甲基他莫昔芬/依西美坦比值对他莫昔芬治疗进行简化的 CYP2D6 表型分析。
Breast. 2020 Dec;54:229-234. doi: 10.1016/j.breast.2020.10.008. Epub 2020 Oct 21.
6
Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen.六项临床研究的综合数据分析指向他莫昔芬的模型指导精准给药。
Front Pharmacol. 2020 Mar 31;11:283. doi: 10.3389/fphar.2020.00283. eCollection 2020.
7
CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer.CYP2D6 基因型预测乳腺癌患者他莫昔芬停药和预后。
J Clin Oncol. 2020 Feb 20;38(6):548-557. doi: 10.1200/JCO.19.01535. Epub 2019 Dec 4.
8
Tamoxifen inhibits cell proliferation by impaired glucose metabolism in gallbladder cancer.他莫昔芬通过损害胆囊癌细胞的糖代谢抑制细胞增殖。
J Cell Mol Med. 2020 Jan;24(2):1599-1613. doi: 10.1111/jcmm.14851. Epub 2019 Nov 28.
9
Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.乳腺癌患者个体内递增剂量的选择性雌激素受体调节剂的药物基因组学-药代动力学研究。
Breast Cancer. 2019 Sep;26(5):535-543. doi: 10.1007/s12282-019-00952-9. Epub 2019 Feb 7.
10
Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People.细胞色素 P450 遗传变异与美国印第安人和阿拉斯加原住民人群中他莫昔芬生物转化相关。
Clin Transl Sci. 2018 May;11(3):312-321. doi: 10.1111/cts.12542. Epub 2018 Feb 13.
本文引用的文献
1
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.关于：绝经后内分泌反应性乳腺癌患者的CYP2D6基因分型与他莫昔芬反应：国际乳腺癌研究组1-98试验
J Natl Cancer Inst. 2012 Aug 22;104(16):1264; author reply 1266-8. doi: 10.1093/jnci/djs304. Epub 2012 Jul 31.
2
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.回复：绝经后内分泌反应性乳腺癌患者的CYP2D6基因分型与他莫昔芬反应：国际乳腺癌研究组1-98试验 以及 回复：CYP2D6和UGT2B7基因分型与他莫昔芬治疗的乳腺癌患者复发风险
J Natl Cancer Inst. 2012 Aug 22;104(16):1263-4; author reply 1266-8. doi: 10.1093/jnci/djs312. Epub 2012 Jul 31.
3
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.回复：绝经后内分泌反应性乳腺癌患者的CYP2D6基因分型与他莫昔芬反应：国际乳腺癌研究组1-98试验
J Natl Cancer Inst. 2012 Aug 22;104(16):1265-6; author reply 1266-8. doi: 10.1093/jnci/djs305. Epub 2012 Jul 31.
4
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.细胞色素P450 2D6基因分型作为绝经后女性辅助性他莫昔芬获益的标志物：经验教训
J Natl Cancer Inst. 2012 Mar 21;104(6):427-8. doi: 10.1093/jnci/djs139. Epub 2012 Mar 6.
5
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.CYP2D6 基因型与内分泌治疗反应性乳腺癌绝经后妇女的关系：乳腺国际研究组 1-98 试验。
J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.
6
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.CYP2D6 和 UGT2B7 基因型与他莫昔芬治疗的乳腺癌患者复发风险。
J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6.
7
Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.根据 CYP2D6 基因型和依西美坦水平增加乳腺癌患者的他莫昔芬剂量：对活性代谢物异构体和抗雌激素活性评分的影响。
Clin Pharmacol Ther. 2011 Oct;90(4):605-11. doi: 10.1038/clpt.2011.153. Epub 2011 Sep 7.
8
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.基因指导的他莫昔芬剂量增加了 CYP2D6 代谢降低的女性中活性代谢物的暴露：一项多中心研究。
J Clin Oncol. 2011 Aug 20;29(24):3232-9. doi: 10.1200/JCO.2010.31.4427. Epub 2011 Jul 18.
9
Personalized tamoxifen: what is the best way forward?个性化他莫昔芬治疗：最佳前进方向是什么？
J Clin Oncol. 2011 Aug 20;29(24):3206-8. doi: 10.1200/JCO.2011.36.3895. Epub 2011 Jul 18.
10
Preemptive pharmacogenetic testing: insufficient data equal unsatisfactory guidance.预防性药物遗传学检测：数据不足导致指导意见不尽人意。
Ann Intern Med. 2011 Jun 21;154(12):842-4. doi: 10.7326/0003-4819-154-12-201106210-00016.
Zotero 插件